诺和诺德 (Novo Nordisk A/S) 第二季度业绩电话会议重点
· finance.yahoo.com
诺和诺德 (NYSE:NVO) 报告称，按固定汇率计算，第二季度调整后销售额增长了 7%，这得益于其肥胖症和糖尿病业务中 GLP-1 销量的增长，而较低的实际成交价格和制造相关成本拖累了利润率。首席执行官 Mike Doust
Millar said the product has captured about 90% of the U.S. oral obesity-medication market despite competition entering in early April. Roughly 80% of patients u...